Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.49 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.49 |
| ▸ | THPO | P40225 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.49 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.49 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.49 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8508241 | 0.84 | EGFR (0.47) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL11980596 | 0.83 | KMT2A (0.40) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL7717389 | 0.83 | ALDH1A1 (0.50) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL10686398 | 0.83 | EGFR (0.50) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL5381358 | 0.83 | CYP3A4 (0.42) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL9506412 | 0.80 | EGFR (0.48) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL9417616 | 0.80 | CYP3A4 (0.50) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL6675108 | 0.78 | EGFR (0.52) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL10530057 | 0.76 | EGFR (0.41) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA | |
| SCHEMBL7461415 | 0.75 | ALDH1A1 (0.53) | CYP3A4ALDH1A1SMN1; SMN2HIF1ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8236985-B2 | Compounds and uses thereof | IMPERIAL INNOVATIONS LTD. (GB) | 2012-08-07 | — | — | US | disclosed |
| US-20100063144-A1 | COMPOUNDS AND USES THEREOF | IMPERIAL INNOVATIONS LTD (GB) | 2010-03-11 | — | — | US | disclosed |
| US-7183319-B2 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY | 2007-02-27 | — | — | US | disclosed |
| US-20040029967-A1 | Phenylethylamine derivatives and their use in the treatment of melanoma | RILEY PATRICK ANTHONY (GB) | 2004-02-12 | — | — | US | disclosed |
| EP-1303481-A1 | PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA | Riley, Patrick Anthony (GB) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002008174-A1 | PHENYLETHYLAMINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF MELANOMA | RILEY PATRICK ANTHONY (GB) | 2002-01-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029967-A1 | Phenylethylamine derivatives and their use in the treatment of melanoma | DOHH, DBH, HRH4 | CYP3A4 28/4885ALDH1A1 49/4885SMN1; SMN2 4029/4885 |
| US-20100063144-A1 | COMPOUNDS AND USES THEREOF | HDAC1, HDAC11, HDAC2 | CYP3A4 251/4885ALDH1A1 150/4885SMN1; SMN2 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.